Amanta Healthcare Limited has disclosed that its promoter Bhavesh Girishbhai Patel has increased his stake in the company through open market purchases. The transaction was disclosed under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Transaction Details

The promoter acquired 48,151 equity shares of the company through market purchases executed on February 26, 2026 and February 27, 2026. The shares were purchased through the National Stock Exchange (NSE) platform.

Shareholding Pattern Changes

Following the acquisition, Bhavesh Patel's shareholding in Amanta Healthcare has increased marginally. The transaction represents a strategic investment by the promoter in the company's equity.

Regulatory Compliance

The company submitted the disclosure in Form 'C' to both BSE Limited and National Stock Exchange of India Limited on February 27, 2026. The disclosure was signed by Company Secretary and Compliance Officer Nikhita Dinodia, ensuring compliance with insider trading regulations.

The promoter confirmed that no derivative trading was undertaken in connection with this transaction. The disclosure includes complete details of the promoter's contact information and PAN details as required under SEBI regulations.

Company Information

Amanta Healthcare Limited is listed on both BSE (Scrip Code: 544502) and NSE (Trading Symbol: AMANTA). The company's registered and corporate office is located at 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat.

Amanta Healthcare Limited conducted its first earnings conference call on February 11, 2026, following the release of Q3 and nine-month FY26 financial results. The pharmaceutical company, led by Chairman and Managing Director Bhavesh Patel, outlined ambitious expansion plans and provided detailed insights into its growth strategy during the investor interaction.

Q3FY26 and Nine-Month Performance Overview

The company maintained its growth trajectory with consistent performance across key financial metrics. Management emphasized the transition from an investment-led phase to a structurally profitable growth phase, supported by operational discipline and strategic initiatives.

Major Capacity Expansion Plans Detailed

During the conference call, management provided comprehensive details about ongoing expansion initiatives. The company is implementing a significant capacity enhancement program across both Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) segments.

Bhavesh Patel confirmed that the SteriPort expansion is expected to commence commercial production by April 2026, with full-scale operations anticipated by the end of the financial year. The incremental revenue from SteriPort alone is projected at ₹120 crore, while the combined expansion could generate ₹150 crore in additional revenue.

SteriPort Technology Leadership and Market Position

Management extensively discussed the company's competitive advantages in the two-port IV fluid container system. Patel highlighted that Amanta was the first company in India to introduce SteriPort technology, which utilizes advanced Injection Stretch Blow Moulding (ISBM) technology with random copolymer polypropylene material.

The company's SteriPort containers can withstand sterilization at 125°C, significantly higher than competitors' polyethylene-based products that cannot exceed 109°C. This technical superiority provides absolute sterilization and reduces contamination risks in critical care applications.

Financial Projections and Debt Management Strategy

CFO Paras Mehta outlined the company's financial roadmap, projecting revenues of approximately ₹400 crore for FY27 from SteriPort expansion alone. The management detailed their debt reduction strategy, targeting annual repayments of ₹35-40 crore through improved cash flows.

Solar Power Initiative and Cost Optimization

The company announced a 10.8 megawatt captive solar power plant investment, expected to be operational by May 2026. This initiative is projected to generate annual cost savings of ₹9 crore at the EBITDA level, enhancing operational efficiency and sustainability.

Management emphasized that despite taking additional debt for the solar project, the net debt position will improve due to accelerated repayments from enhanced cash flows and operational savings.